Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Criteria:

Histologically proven uveal melanoma
Must have documented disease progression during or after =< 1 prior systemic treatment
Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan
No tumor involving major vessels
Zubrod performance status 0-1
Absolute neutrophil count > 1,500/mm^3
Platelet count > 100,000/mm^3
Creatinine =< 2 times upper limit of normal (ULN)
Bilirubin =< 2 times ULN
SGOT or SGPT =< 2 times ULN (5 times ULN if hepatic metastasis present)
INR in range (usually between 2 and 3)
No active bleeding
No bleeding diathesis, active coagulopathy, or pathological condition that carries a high risk of bleeding
No condition (e.g., gastrointestinal tract disease) affecting ability to take oral medication or requiring IV alimentation
Not pregnant or nursing
Fertile patients must use effective contraception
No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or any other cancer for which the patient has been disease-free for 5 years
At least 28 days since prior systemic treatment for this disease comprising 1 of the following: single chemotherapy agent/regimen; single immunotherapy agent/regimen; single investigational treatment agent/regimen
At least 21 days since prior major surgery
No prior sorafenib or any other agents targeting raf kinase or vascular endothelial growth factor (VEGF) or VEGF receptor
No prior surgical procedures affecting absorption
No concurrent systemic corticosteroid therapy
Topical and/or inhaled steroids are allowed
No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, and phenobarbital), rifampin, or Hypericum perforatum (St. John's wort)
No prophylactic granulocyte/platelet colony-stimulating factors during the first course of treatment
Concurrent full-dose oral anticoagulants (e.g., warfarin) are allowed provided all of the following criteria are met: in-range INR ; stable dose of oral anticoagulant; no active bleeding or high risk of bleeding
Stage IV disease
No known varices
No uncontrolled hypertension with systolic blood pressure (BP) > 140 mm Hg or diastolic BP > 90 mm Hg
No significant traumatic injury within the past 21 days
No active, uncontrolled peptic ulcer disease